Physicochemical Properties
| Molecular Formula | C15H6D4O5 | 
| Molecular Weight | 274.26 | 
| Exact Mass | 274.077 | 
| CAS # | 187960-08-3 | 
| Related CAS # | Genistein;446-72-0 | 
| PubChem CID | 11821800 | 
| Appearance | White to off-white solid powder | 
| Density | 1.5±0.1 g/cm3 | 
| Boiling Point | 555.5±50.0 °C at 760 mmHg | 
| Flash Point | 217.1±23.6 °C | 
| Vapour Pressure | 0.0±1.6 mmHg at 25°C | 
| Index of Refraction | 1.732 | 
| LogP | 2.96 | 
| Hydrogen Bond Donor Count | 3 | 
| Hydrogen Bond Acceptor Count | 5 | 
| Rotatable Bond Count | 1 | 
| Heavy Atom Count | 20 | 
| Complexity | 411 | 
| Defined Atom Stereocenter Count | 0 | 
| SMILES | [2H]C1=C(C(=C(C(=C1C2=COC3=CC(=CC(=C3C2=O)O)O)[2H])[2H])O)[2H] | 
| InChi Key | TZBJGXHYKVUXJN-RHQRLBAQSA-N | 
| InChi Code | InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H/i1D,2D,3D,4D | 
| Chemical Name | 5,7-dihydroxy-3-(2,3,5,6-tetradeuterio-4-hydroxyphenyl)chromen-4-one | 
| HS Tariff Code | 2934.99.9001 | 
| Storage | Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month | 
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) | 
Biological Activity
| ln Vitro | Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1]. | 
| References | [1]. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345-51. [3]. Environmentally Relevant Dose of Bisphenol A Does Not Affect Lipid Metabolism and Has No Synergetic or Antagonistic Effects on Genistein's Beneficial Roles on Lipid Metabolism. PLoS One. 2016 May 12;11(5):e0155352. | 
Solubility Data
| Solubility (In Vitro) | DMSO : 50 mg/mL (182.31 mM) | 
| Solubility (In Vivo) | Solubility in Formulation 1:  ≥ 1.25 mg/mL (4.56 mM) (saturation unknown)  in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (4.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) | 
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6462 mL | 18.2309 mL | 36.4618 mL | |
| 5 mM | 0.7292 mL | 3.6462 mL | 7.2924 mL | |
| 10 mM | 0.3646 mL | 1.8231 mL | 3.6462 mL | 
 Chemical Structure.png)